BACKGROUND: Reports have shown correlations between the immune response to vector saliva and Leishmaniasis outcome. We followed dogs in an endemic area for two years characterizing resistance or susceptibility to canine visceral leishmaniasis (CVL) according to Leishmania infantum diagnosis and clinical development criteria. Then, we aimed to identify a biosignature based on parasite load, serum biological mediators' interactions, and vector exposure intensity associated with CVL resistance and susceptibility. METHODOLOGY/PRINCIPAL FINDINGS: A prospective two-year study was conducted in an area endemic for CVL. Dogs were evaluated at 6-month intervals to determine infection, clinical manifestations, immune profile, and sandfly exposure. CVL resistance or susceptibility was determined upon the conclusion of the study. After two years, 78% of the dogs were infected with L. infantum (53% susceptible and 47% resistant to CVL). Susceptible dogs presented higher splenic parasite load as well as persistence of the parasite during the follow-up, compared to resistant ones. Susceptible dogs also displayed a higher number of correlations among the investigated biological mediators, before and after infection diagnosis. At baseline, anti-saliva antibodies, indicative of exposure to the vector, were detected in 62% of the dogs, reaching 100% in one year. Higher sandfly exposure increased the risk of susceptibility to CVL by 1.6 times (CI: 1.11-2.41). We identified a discriminatory biosignature between the resistant and susceptible dogs assessing splenic parasite load, interaction of biological mediators, PGE2 serum levels and intensity of exposure to sandfly. All these parameters were elevated in susceptible dogs compared to resistant animals. CONCLUSIONS/SIGNIFICANCE: The biosignature identified in our study reinforces the idea that CVL is a complex multifactorial disease that is affected by a set of factors which are correlated and, for a better understanding of CVL, should not be evaluated in an isolated way.
BACKGROUND: Reports have shown correlations between the immune response to vector saliva and Leishmaniasis outcome. We followed dogs in an endemic area for two years characterizing resistance or susceptibility to caninevisceral leishmaniasis (CVL) according to Leishmania infantum diagnosis and clinical development criteria. Then, we aimed to identify a biosignature based on parasite load, serum biological mediators' interactions, and vector exposure intensity associated with CVL resistance and susceptibility. METHODOLOGY/PRINCIPAL FINDINGS: A prospective two-year study was conducted in an area endemic for CVL. Dogs were evaluated at 6-month intervals to determine infection, clinical manifestations, immune profile, and sandfly exposure. CVL resistance or susceptibility was determined upon the conclusion of the study. After two years, 78% of the dogs were infected with L. infantum (53% susceptible and 47% resistant to CVL). Susceptible dogs presented higher splenic parasite load as well as persistence of the parasite during the follow-up, compared to resistant ones. Susceptible dogs also displayed a higher number of correlations among the investigated biological mediators, before and after infection diagnosis. At baseline, anti-saliva antibodies, indicative of exposure to the vector, were detected in 62% of the dogs, reaching 100% in one year. Higher sandfly exposure increased the risk of susceptibility to CVL by 1.6 times (CI: 1.11-2.41). We identified a discriminatory biosignature between the resistant and susceptible dogs assessing splenic parasite load, interaction of biological mediators, PGE2 serum levels and intensity of exposure to sandfly. All these parameters were elevated in susceptible dogs compared to resistant animals. CONCLUSIONS/SIGNIFICANCE: The biosignature identified in our study reinforces the idea that CVL is a complex multifactorial disease that is affected by a set of factors which are correlated and, for a better understanding of CVL, should not be evaluated in an isolated way.
Authors: Jennifer E Lykens; Catherine E Terrell; Erin E Zoller; Senad Divanovic; Aurelien Trompette; Christopher L Karp; Julio Aliberti; Matthew J Flick; Michael B Jordan Journal: J Immunol Date: 2009-12-14 Impact factor: 5.422
Authors: Ana Paula Souza; Bruno Bezerril Andrade; Dorlene Aquino; Petter Entringer; José Carlos Miranda; Ruan Alcantara; Daniel Ruiz; Manuel Soto; Clarissa R Teixeira; Jesus G Valenzuela; Camila Indiani de Oliveira; Cláudia Ida Brodskyn; Manoel Barral-Netto; Aldina Barral Journal: PLoS Negl Trop Dis Date: 2010-03-23
Authors: Fred Luciano Neves Santos; Wayner Vieira de Souza; Michelle da Silva Barros; Mineo Nakazawa; Marco Aurélio Krieger; Yara de Miranda Gomes Journal: Am J Trop Med Hyg Date: 2016-03-14 Impact factor: 2.345
Authors: Bruno B Andrade; Amrit Singh; Gopalan Narendran; Melissa E Schechter; Kaustuv Nayak; Sudha Subramanian; Selvaraj Anbalagan; Stig M R Jensen; Brian O Porter; Lis R Antonelli; Katalin A Wilkinson; Robert J Wilkinson; Graeme Meintjes; Helen van der Plas; Dean Follmann; Daniel L Barber; Soumya Swaminathan; Alan Sher; Irini Sereti Journal: PLoS Pathog Date: 2014-10-02 Impact factor: 6.823
Authors: Angela J Toepp; Glória R G Monteiro; José F V Coutinho; Adam Leal Lima; Mandy Larson; Geneva Wilson; Tara Grinnage-Pulley; Carolyne Bennett; Kurayi Mahachi; Bryan Anderson; Marie V Ozanne; Michael Anderson; Hailie Fowler; Molly Parrish; Kelsey Willardson; Jill Saucier; Phyllis Tyrell; Zachary Palmer; Jesse Buch; Ramaswamy Chandrashekar; Grant D Brown; Jacob J Oleson; Selma M B Jeronimo; Christine A Petersen Journal: Parasit Vectors Date: 2019-01-23 Impact factor: 3.876
Authors: Tiffany Weinkopff; Camila I de Oliveira; Augusto M de Carvalho; Yazmin Hauyon-La Torre; Aline C Muniz; Jose Carlos Miranda; Aldina Barral; Fabienne Tacchini-Cottier Journal: PLoS Negl Trop Dis Date: 2014-01-09